The TGA has approved Vertex's TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include children with cystic fibrosisaged two to five who have at least one F508del mutation in the CF transmembrane conductance regulator gene. …
TGA extends approval for Vertex's cystic fibrosis therapy ahead of PBAC consideration
February 8, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
Australia’s life sciences sector emerges as fast growing, globally connected powerhouse
May 21, 2026 - - Latest News -
They used to forecast growth, it was not real and couldn't be used, and it made the program a target for cuts
May 21, 2026 - - Latest News -
New report reveals how AI is now deciding which healthcare brands Australians see online
May 21, 2026 - - Latest News -
Medicine shortages and workforce gaps threaten the sustainability of Australian care
May 21, 2026 - - Latest News -
Sanofi therapy wins Australian registration for non-relapsing secondary progressive MS
May 20, 2026 - - Latest News -
Owen Smith: 'We are ready to negotiate. We are ready to be a genuine partner'
May 19, 2026 - - Latest News -
Australia bets on translational science to turn discovery into global impact
May 19, 2026 - - Latest News